- Home
- LOVE vs NBP Comparison
LOVE vs NBP Comparison
Compare LOVE & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOVE | NBP |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.3M | 173.5M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | LOVE | NBP |
|---|---|---|
| Price | $16.15 | $1.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $25.00 | $9.00 |
| AVG Volume (30 Days) | 188.6K | ★ 515.3K |
| Earning Date | 06-11-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $697,115,000.00 | N/A |
| Revenue This Year | $4.63 | N/A |
| Revenue Next Year | $6.40 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.42 | N/A |
| 52 Week Low | $10.33 | $1.46 |
| 52 Week High | $20.88 | $5.19 |
Technical Indicators
Market Signals| Indicator | LOVE | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 56.34 | 41.09 |
| Support Level | $14.43 | N/A |
| Resistance Level | $17.69 | $1.67 |
| Average True Range (ATR) | 1.06 | 0.12 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 74.52 | 35.55 |
Price Performance
Historical ComparisonAbout LOVE The Lovesac Company
The Lovesac Co designs, manufactures and sells alternative furniture which is comprised of modular couches called sactionals and premium foam beanbag chairs called sacs. It also offers other accessories such as sactional-specific drink holders, Footsac blankets, decorative pillows, fitted seat tables, and ottomans. Its products are sold across the United States through its website or company-owned retail stores which are used in homes and offices. The majority of the firm's revenue is derived from the sale of Sactionals.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.